# SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

> **NCT07080619** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin ConjuStar Biologics Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer
- HR+ Breast Cancer

## Interventions

- **DRUG:** SC-101

## Key facts

- **NCT ID:** NCT07080619
- **Lead sponsor:** Tianjin ConjuStar Biologics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-20
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07080619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07080619, "SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07080619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*